NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma Inc (NASDAQ:TBPH) announced its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.05). The biopharmaceutical company had revenue of $12.43 million for the quarter, compared to the consensus estimate of $13.33 million. View Theravance Biopharma's Earnings History.

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Theravance Biopharma.

Theravance Biopharma will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokers have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $35.75 in the next year. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.

Media headlines about TBPH stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Theravance Biopharma earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Theravance Biopharma.

Theravance Biopharma saw a decrease in short interest during the month of January. As of January 15th, there was short interest totalling 2,640,000 shares, a decrease of 5.4% from the December 31st total of 2,790,000 shares. Based on an average trading volume of 307,900 shares, the days-to-cover ratio is presently 8.6 days. Approximately 6.9% of the company's stock are sold short. View Theravance Biopharma's Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Exelixis (EXEL), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Verizon Communications (VZ), Corbus Pharmaceuticals (CRBP) and GW Pharmaceuticals PLC- (GWPH).

Theravance Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Link Fund Solutions Ltd (9.25%), State Street Corp (1.69%), Chescapmanager LLC (1.67%), Jacobs Levy Equity Management Inc. (0.80%), Candriam Luxembourg S.C.A. (0.49%) and Charles Schwab Investment Management Inc. (0.47%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma.

TBPH stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Citigroup Inc., Virtus ETF Advisers LLC, Bank of America Corp DE, Chicago Equity Partners LLC, New York State Common Retirement Fund, Nisa Investment Advisors LLC and ProShare Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma.

TBPH stock was acquired by a variety of institutional investors in the last quarter, including Link Fund Solutions Ltd, Chescapmanager LLC, Laurion Capital Management LP, Jacobs Levy Equity Management Inc., Credit Suisse AG, First Trust Advisors LP, Cubist Systematic Strategies LLC and California Public Employees Retirement System. View Insider Buying and Selling for Theravance Biopharma.

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TBPH stock can currently be purchased for approximately $25.08.